1. Scrip
  2. >>Focus On Asia
  3. >>India

Is Mittelstand The Missing Piece In India’s Q Quotient?

 
• By Vibha Ravi

Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.

Members of IPA panel on cross industry learning
L to R – Sudarshan Jain – general secretary IPA; Soumitra Bhattacharya – chairman, Bosch; Anshul Gupta - MD and head, healthcare investment banking, Avendus Capital; Jayant D. Patil - director & VP, L&T defence business; Rahul Awasthi - global head of operations, Sun Pharma (Source: Citeline)

While well begun is half done, a German proverb goes “It is idle to swallow the cow and choke on the tail,” implying that it’s unwise to take on a task or challenge without being fully prepared to handle all its components and potential consequences.

India’s drive towards quality improvement in pharma has resulted in tangible results, with an increasing number of manufacturing units having...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

More from Leadership